- Zealand Pharma press release ( OTCPK:ZLDPF ): FY GAAP EPS of - DKK 20.90.
- Revenue of DKK 104M (-4.1% Y/Y).
- Cash, cash equivalents, and marketable securities: DKK 1,117.8 million as of December 31, 2022 (December 31, 2021: DKK 1,428 million).
- Under current planning assumptions, Zealand projects its existing capital resources will be sufficient to fund operations until the middle of 2024.
- 2023 Financial guidance : Revenue anticipated from existing and new license and partnership agreements: No guidance due to uncertain size and timing; Net operating expenses of DKK 800M-DKK 900M.
For further details see:
Zealand Pharma GAAP EPS of -DKK 20.90, revenue of DKK 104M